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ABSTRACT
Objective To evaluate the impact of introduction of
supervision of methadone dosing on deaths related to
overdose ofmethadone in Scotland and England between
1993 and 2008 while controlling for increased
prescribing of methadone.
Design Analysis of annual trends in deaths related to
overdose of methadone in relation to defined daily doses
of methadone prescribed.
Setting Scotland and England.
Population Deaths in whichmethadone was coded as the
only drug involved or as one of the drugs implicated.
Main outcome measure Annual OD4-methadone index
(number of deathswithmethadone implicated permillion
defined daily doses of methadone prescribed in that
year).
Results OD4-methadone declined substantially over the
four epochs of four years between 1993 and 2008. It
decreased significantly (P<0.05) in 10 of 12 epoch
changes: in Scotland from 19.3 (95% confidence interval
15 to 24) to 4.1 (2.8 to 5.4) and finally to 3.0 (2.4 to 3.5)
for methadone only deaths (and from 58 to 29 to 14 for
deaths with any mention of methadone); in England from
27.1 (25 to 29) to 24.8 (23 to 27) and finally to 5.8 (5.3 to
6.3) for methadone only deaths (and from 46 to 42 to 12
for deaths with any mention of methadone). The
decreases in OD4-methadone were closely related to the
introduction of supervised dosing of methadone in both
countries, first in Scotland (1995-2000) and later in
England (1999-2005). These declines occurred over
periods of substantial increases in prescribing of
methadone (18-fold increase in defined daily doses per
million population annually in Scotland and sevenfold
increase in England).
Conclusions Introduction of supervised methadone
dosing was followed by substantial declines in deaths
related to overdose of methadone in both Scotland and
England. OD4-methadone index analyses, controlled for
substantial increases in methadone prescribing in both
countries, identified at least a fourfold reduction in
deaths due to methadone related overdose per defined
daily dose (OD4-methadone) over this period.
INTRODUCTION
Heroin and other opiates contribute disproportio-
nately to deaths from drug overdoses, compared with
their low prevalence of use in many developed
countries.1-3 Deaths due to overdose of opiates, for
example, accounted for 9% of deaths in young Austra-
lian adults under the age of 50 in 1998 and for more
than10% in several European cities despite the fact that
they were used by less than 1% of adults in any year.4 5
We need to understand better the factors driving these
deaths if they are to be reduced.Opioids are implicated
in more than three quarters of all illicit drug related
deaths in the United Kingdom.2-7
The prescribed opioid methadone is used as mainte-
nance treatment for opioid dependence, leading to a
major reduction in deaths from overdose.8-14 Almost
all methadone is prescribed for treatment of opioid
addiction; for example, 99.5% of all methadone pre-
scriptions in Scotland in 2008-9 were for “treatment
of substance dependence.”6 The vast majority of this
is prescribed as oral liquid/linctus: 100% in Scotland
and 96% in England.6 15
Careless or unsanctioned use of methadone contri-
butes to deaths due to overdose.2During the 1990s, for
example, methadone was implicated in as many drug
relateddeaths in theUKaswasheroin.16 17Recommen-
dations were made for UK clinical practice to align
with other countries, with the introduction of new
arrangements for supervised consumption of
methadone,18 19 and major change occurred over the
past decade.15
Methadone prescribing practice in theUKwas chan-
ged in the mid-late 1990s, with the aim of reducing
deaths related to overdose ofmethadone; daily dispen-
sing and supervision of methadone dosing were intro-
duced or increased to reduce diversion.2 18 19 These
changes occurred first in Scotland, from 1992
onwards,20-29 and only later in England (fig 1). 30-37
We examined the impact of these changes on deaths
related to overdose of methadone per million defined
daily doses (see later for definition) of prescribed
methadone: the OD4-methadone index. We
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examined whether reductions in OD4-methadone
index (both narrowly and broadly defined) coincided
with the period of introduction of supervision of
methadone dosing in Scotland and England.
METHODS
We defined the annual OD4-methadone index as the
number of deaths with methadone implicated per mil-
lion defined daily doses of methadone prescribed in
that year. The OD4-methadone index enabled us to
examine methadone’s contribution to deaths due to
opioid overdose while controlling for expansion of
methadone treatment during the study period. We
defined methadone related deaths in two ways: deaths
due to overdose inwhichmethadonewas the only drug
present and deaths due to overdose in which metha-
done was one of two or more drugs that were present.
These calculations therefore produce two versions of
theOD4-methadone index: theOD4-methadone (sole
drug) index and the OD4-methadone (any mention)
index.
Statistical methods
We examined annual changes within each country
(that is, separately for England andScotland).We addi-
tionally examined the data as four epochs of four years
each and did statistical analysis. In deriving 95% con-
fidence intervals for the OD4-methadone index, we
assumed that the number of deaths due to methadone
overdose per calendar year and per four year epoch
followed a Poisson distribution.
OD4-methadone index
Deaths related to overdose of methadone
We obtained mortality data for Scotland and England
(special retrieval for England only, on request, from
the Office for National Statistics).6 7 We obtained data
on the numbers of drug related deaths in whichmetha-
donewas the “only drug” reported in coroners’ reports
and the number in which it was “one of more than one
drug” reported by coroners.6Coronial processes differ
in practice and definitions between Scotland and Eng-
land, so we examined changes over time within each
country.
Defined daily dose of prescribed methadone
We obtained national data separately, by special
request, on the total quantity of methadone prescribed
annually by theNHS in Scotland and inEngland (Gen-
eral Register Office Scotland and Department of
Health NHS Statistics) for 1993-2008 (tables 1 and
2).We arranged for retrieval of theseNHSprescription
data for all instances in which the reported indication
was “treatment of substance dependence.”
We used theWorld Health Organization’s definition
of defined daily dose as “the assumed average
Scotland
1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007
1992: supervised
dosing of methadone
introduced in two general
practices in Glasgow20 21
1992-5 identified as period when supervised methadone dosing was introduced and 1995-2000 as period when it became widespread in Scotland
1995-2000: Scotland-wide surveys of community
pharmacists showed supervised methadone dosing
increased from 33% in 1995-6 to 65% of all
prescriptions in 200027 28
1995: became city-wide in Glasgow22-24
for at least first 12 months of treatment.
Rapidly spread to elsewhere in Scotland25 26
2000-6: no further change according to survey of community
pharmacists in 200629
England
1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007
1996: Task Force for England
recommends  “pilot projects
to investigate the potential for
pharmacists to expand the
range of services they offer to
drug misusers, including
supervised consumption of
controlled drugs”18
1996-8 identified as period when supervised methadone dosing was introduced and 1999-2005 as period when it diffused throughout England
2000: ACMD Report on Drug-Related Deaths
recommends supervision for first 6 months of
treatment2
1999: supervised methadone consumption recommended for
first 3 months of treatment by DH’s “Orange Guidelines19 35 36
1996 onwards: services gradually begin to introduce supervised consumption30-33
Mid-90s: high rate
of methadone
related deaths
identified by
international
standards1 2; no
supervised
methadone
1997: survey of health
authorities finds 22% now
reimburse community
pharmacists for supervising
methadone consumption and
37% planning to do so34
2005: national survey
of community
pharmacists
supervised
consumption
increased from zero
in 1995 to 36% of all
methadone
prescriptions14 15 37
Fig 1 | Timelines of introduction and spread of supervision of methadone consumption in Scotland and England
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maintenance dose per day for a drug used for its main
indication in adults.”38 This provided an estimate of
consumption in a fixedunit ofmeasurement that is inde-
pendent of price and formulation and so enabled assess-
mentof trends inmethadoneuse.Weused amethadone
daily dose of 60 mg as the defined daily dose because
thiswas the lowerpointof the recommendeddose range
and was close to the average dose prescribed in the UK
over the period of study—namely, 47.3 (SD 28.2) mg in
1995 and 56.3 (28.7) mg in 2005.15193739
Calculation of the OD4-methadone index
To examine the temporal relation betweenmethadone
prescribing and the number of methadone related
deaths, we calculated theOD4-methadone index sepa-
rately for Scotland and England in respect of deaths in
which methadone was the sole drug mentioned (OD4-
methadone (sole drug)) and deaths in which there was
any mention of methadone (OD4-methadone (any
mention)).
Timing of policy initiative
Supervision of methadone consumption was intro-
duced in Scotland in two general practices in Glasgow
in 1992 and subsequently across Glasgow, and then
widely throughout Scotland during 1995-2000 (fig 1,
top). In England, no supervised consumption existed
at the time of a national survey of pharmacists in 1995;
it began to appear in 1996 and spread more slowly
across England throughout 1999-2005 (fig 1, bottom).
RESULTS
Over the 16 year period 1993-2008, 1307 deaths
related to overdose ofmethadone occurred in Scotland
and4317 inEngland.Methadonewas the sole reported
drug in 258 (20%) of these deaths in Scotland and in
2343 (54%) in England.
Methadone prescribing
Over the 16 year study period, 65million defined daily
doses of methadone were prescribed in Scotland
(table 1) and 198 million in England (table 2 ). Rates
of prescribing increased dramatically over the study
period (1993-2008) in both countries. In Scotland, it
increased from fewer than 0.1 million defined daily
doses per million population in the early 1990s to 1.8
million by 2008 (table 1). In England, methadone pre-
scribing increased from approximately 0.1 million
defined daily doses per million population in 1993 to
just over 0.5 million by 2008 (table 2).
Deaths related to overdose of methadone
In Scotland (table 1), deaths related to overdose of
methadone peaked in 1996 and 1997 (and in 1996 for
methadone as sole drug); they then declined for the
next four years and remained at this lower level for
several years. Methadone only deaths began to
increase again in the mid-2000s.
In England (table 2), deaths related to overdose of
methadone peaked in 1997 and 1998 (and in 1997 for
methadone as sole drug) and thendeclined for six years
after 1998. They began to increase again before the
final four year epoch (table 3) but had not regained
their 1997 level by 2008.
OD4-methadone index calculations
The OD4-methadone index for both deaths due to
overdose with methadone only and those in which
methadone was mentioned declined substantially in
both Scotland and England.
In Scotland, the OD4-methadone (sole drug) index
declined after 1996; annual deaths due to overdose
decreased from around 20 per million defined daily
doses to only two by 1999. From 2000 onwards, this
OD4 index remainedbelow five (table 1 and fig 2, top).
Thus, over a four year period (1997-2000), the deaths
withmethadone reported as sole drug reduced from20
to three per million defined daily doses and remained
around this lower level thereafter. The reduction in
deaths with any mention of methadone was more gra-
dual, from 58 deaths per million defined daily doses in
the first four year epoch to 29 in the second and there-
after to 18 and 14 (tables 1 and 3; fig 2, top).
In England, the OD4-methadone (sole drug) index
was at a high level until 1998; annual deaths due to
overdose in which only methadone was reported
Table 1 | Methadone data—Scotland (population 5.2 million in 2008)
1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008
Deaths
Methadone only 10 21 21 27 20 8 5 5 8 14 12 9 20 35 29 14
Any mention of methadone 25 55 58 99 87 64 62 56 71 99 87 80 72 97 114 181
Quantity prescribed
Methadone kg (mg × 1 million) 31.0 51.7 72.1 90.8 112.3 127.7 145.5 173.6 210.0 255.0 308.1 363.2 421.9 473.1 520.6 572.5
Year on year increase (%) – 66.7 39.6 25.9 23.6 13.8 13.9 19.3 21.0 21.4 20.8 17.9 16.2 12.2 10.0 10.0
Defined daily dose (DDD) calculations
Methadone DDDs—60 mg daily doses
(millions)
0.52 0.86 1.20 1.51 1.87 2.13 2.43 2.89 3.50 4.25 5.13 6.05 7.03 7.89 8.68 9.54
OD4 calculations
OD4 score (methadone only) (per million) 19.4 24.4 17.5 17.8 10.7 3.8 2.1 1.7 2.3 3.3 2.3 1.5 2.8 4.4 3.3 1.5
OD4 score (any mention of methadone)
(per million)
48.4 63.9 48.2 65.4 46.5 30.1 25.6 19.4 20.3 23.3 16.9 13.2 10.2 12.3 13.1 19.0
RESEARCH
BMJ | ONLINE FIRST | bmj.com page 3 of 7
ranged from 25 to 35 per million defined daily doses.
This OD4 decreased thereafter, and deaths steadily
declined over the next six years to around six per mil-
lion defined daily doses and remained at this lower
level (table 2 and fig 2, bottom). A similar reduction
in deaths with any mention of methadone occurred;
the OD4-methadone (any mention) index decreased
from 46 and 42 deaths per million defined daily doses
in the first and second four year epochs to 17 and 11
thereafter (tables 2 and 3; fig 2, bottom).
Relation between changes in OD4 and supervised
consumption of methadone
We observed three distinct phases in both of the OD4-
methadone index scores (methadone only and any
mention) in both Scotland and England: an initial
steady state, a rapid decline, and then a new steady
state. The initial steady state for the OD4-methadone
(sole drug) index in Scotland was around 19 in 1993-6
(table 3 and fig 2, top). This was followed by rapid
reduction of OD4-methadone down to four during
1997-2000. The reduction tracks the timing of Scot-
land’s adoption of supervised methadone consump-
tion between 1995 and 2000 (fig 1, top).
The initial steady state for theOD4-methadone (sole
drug) index in England exceeded 25 (that is, more than
25 deaths per million defined daily doses) until 1998.
This was followed by a decline over a more extended
period (1998-2005) to a new lower level of around six
deaths per million defined daily doses (tables 2 and 3;
fig 2, bottom). The timing of these changes coincided
with the later and more gradual implementation of
supervised methadone consumption in England
between 1999 and 2005 (fig 1, bottom).
Finally, we examined these data in four epochs of
four years each. In Scotland, the largest decline in
OD4-methadone occurred between the first and sec-
ond epochs (table 3). In England, by contrast, the
most pronounced decline occurred between the sec-
ond and third epochs.All changeswere statistically sig-
nificant (P≤0.02) for transitions between epochs for
OD4 index involving both methadone only and any
mention of methadone, except for the two epoch
changes marked with an asterisk in table 3.
DISCUSSION
This study shows the value of the OD4-methadone
index expressed in terms of defined daily dose in asses-
sing the impact of policy changes on the safety of
methadone prescribing. Our findings show a remark-
able improvement in the safety ofmethadone prescrib-
ing in both Scotland andEngland, particularly over the
period 1995-2004.
The absence of systematic tracking of deaths has
meant that this substantial improvement in the safety
of methadone treatment has hitherto been neither
detected nor quantified. We found that the timing of
these changes was precise and was related to a specific
change in clinical practice that occurred at different
times in the two countries—namely, the widespread
supervision of methadone dosing during the early
months of treatment. The previous failure to detect
this improved safety may be because the change
occurred over a period of very substantial increases
in prescribing of methadone.
Other possible explanations
Before cautiously accepting this inference that the
decline in the rate of deaths due to methadone over-
dose was the result of this increased supervision of dos-
ing, we need to evaluate and exclude other possible
explanations of the decline in OD4-methadone.
Firstly, we can exclude the possibility that the decline
in OD4-methadone reflects either a reduction in avail-
ability of heroin, such as occurred in Australia after
2001,40 or a decline in the number of people using her-
oin. No evidence exists of any sustained heroin short-
age or reduction in the number of heroin users in the
UK over the study period. In fact, all indices of the
availability and use of heroin, including deaths due to
heroin overdose, rose steadily during the study
period,41 as did the number of heroin dependent peo-
ple being treated by methadone maintenance.42
The same is true for changes in the route of opiate
use, such as increased use of non-injecting routes.
Table 2 | Methadone data—England (population 51.4 million in 2008)
1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008
Deaths
Methadone only 113 144 169 179 268 218 171 144 121 86 71 104 94 121 153 187
Any mention of methadone 195 254 286 300 402 377 323 257 229 191 189 216 209 229 305 355
Quantity prescribed
Methadone kg (mg × 1 million) 262.6 305.9 360.2 413.2 460.7 472.9 490.1 517.8 557.7 633.6 772.2 931.1 1127.5 1343.0 1530.2 1730.0
Year on year increase (%) – 16.5 17.7 14.7 11.5 2.6 3.6 5.7 7.7 13.6 21.9 20.6 21.1 19.1 13.9 13.1
Defined daily dose (DDD) calculations
Methadone DDDs—60 mg daily
doses (millions)
4.38 5.10 6.00 6.89 7.68 7.88 8.17 8.63 9.30 10.56 12.87 15.52 18.79 22.38 25.50 28.83
OD4 calculations
OD4 score (methadone only)
(per million)
25.8 28.2 28.2 26.0 34.9 27.7 20.9 16.7 13.0 8.1 5.5 6.7 5.0 5.4 6.0 6.5
OD4 score (any mention of
methadone) (per million)
44.6 49.8 47.6 43.6 52.4 47.8 39.5 29.8 24.6 18.1 14.7 13.9 11.1 10.2 12.0 12.3
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Heroin “chasers” have fewer fatal overdoses than do
heroin injectors,43 and a considerable proportion of
UK heroin users are chasers.44 45 No evidence exists,
however, that the proportion of chasers increased
over the study period. Even if this had occurred, it
would be more likely to reduce deaths due to heroin
than deaths involving methadone. It would also not
explain the difference in timing between Scotland
and England.
Other changes in methadone prescribing and dis-
pensing are unlikely to explain the decline. Recom-
mendations were made to increase doses and rates of
daily dispensing of methadone, but doses increased
only slowly and the increase in daily dispensing was
modest by comparison with the very substantial
expansion of supervised methadone consumption in
both countries.37 46
Data sources and collection
The definition of a death related to overdose of metha-
done can be restrictive (methadone only) or inclusive
(any mention of methadone). Both definitions depend
on toxicological assessments and the reporting prac-
tices of coroners. We measured deaths in both ways
tominimise the impact of these definitions on our find-
ings. The fact that both measures showed parallel
changes albeit at different levels over the study period
is reassuring. Both also showed the same difference in
timing between the two countries. The decline was
somewhat faster for methadone only deaths, which
one may expect to be more sensitive to any benefits
of supervised dosing.
Incompleteness of the data is unlikely to explain the
decline. Although dosing data were not available for
non-NHS (“private”) practice or for methadone dis-
pensing at on-site hospital pharmacies, these practices
relate to only small numbers of prescriptions. Only
1.5% of all methadone prescriptions were from private
practice in 1995 and 1.0% in 2005,15 37 and on-site dis-
pensing in England was rare, accounting for probably
less than 1% of dispensing.
Conclusions and policy implications
This is the first study to use publicly availablemortality
data to assess whether increased supervision of metha-
done has, as intended, reduced deaths due to overdose
involving prescribed methadone. The OD4 index can
also potentially be used to assess the safety of other
Table 3 | Changes in OD4 score over four epochs of four years
Outcome 1993-6 1997-2000 2001-4 2005-8
Scotland (population 5.2 million in 2008)
Drug related deaths: methadone as only drug 79 38 43 98
Drug related deaths: any mention of methadone 237 269 337 464
Quantity of methadone prescribed (mg × 1 million) 245.6 559.1 1136.3 1988.1
Implied methadone patient years (DDD (60 mg)/365) 11 215 25 530 51 889 90 781
OD4 score: methadone only (95% CI) 19.3 (15 to 24) 4.1 (2.8 to 5.4) 2.3 (1.6 to 2.9)† 3.0 (2.4 to 3.5)*
OD4 score: any mention of methadone (95% CI) 57.9 (50 to 65) 28.9 (25 to 32) 17.8 (15.9 to19.7) 14.0 (12.7 to 15.3)‡
England (population 51.4 million in 2008)
Drug related deaths: methadone as only drug 605 801 382 555
Drug related deaths: any mention of methadone 1035 1359 825 1098
Quantity of methadone prescribed (mg × 1 million) 1341.9 1941.5 2894.6 5730.7
Implied methadone patient years (DDD (60 mg)/365) 61 274 88 653 132 174 261 676
OD4 score: methadone only (95% CI) 27.1 (24.9 to 29.2) 24.8 (23.0 to 26.5)* 7.9 (7.1 to 8.7) 5.8 (5.3 to 6.3)
OD4 score: any mention of methadone (95% CI) 46.3 (43 to 49) 42.0 (40 to 44)§ 17.1 (15.9 to 18.3) 11.5 (10.8 to 12.2)
DDD=defined daily dose.
Z scores are provided when 95% confidence intervals overlap.
*All OD4 changes across epoch were significant, except for those concluding here.
†Z score versus previous epoch=2.42.
‡Z score versus previous epoch=3.25.
§Z score versus previous epoch=2.33.
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forms of treatment for opioid dependence (such as pre-
scription of buprenorphine): these further analyses
should now be done. Our finding of a major reduction
in deaths related to overdose of methadone raises the
question of whether other changes in treatment prac-
tice could achieve even greater reductions in deaths
related to overdose of methadone and other opioids.
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National Statistics (deaths, England), and information services NHS
Scotland and England (prescription data) helpfully did special retrievals
of national data. We are grateful to John Witton for help with securing
these data.
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